Avoid Delivering Therapies for Nonsustained Fast Ventricular Tachyarrhythmia in Patients with Implantable Cardioverter/Defibrillator: The ADVANCE III Trial

Introduction: The purpose of this investigation is to evaluate whether a prolonged detection interval for life threatening ventricular tachyarrhythmia (VT) is able to reduce therapies (Rx) delivered by an implantable cardioverter/defibrillator (ICD). Until now, only the PREPARE trial demonstrated a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiovascular electrophysiology 2009-06, Vol.20 (6), p.663-666
Main Authors: SCHWAB, JOERG O., GASPARINI, MAURIZIO, LUNATI, MAURIZIO, PROCLEMER, ALESSANDRO, KAUP, BERND, SANTI, ELISABETTA, LIGORIO, GUISEPPE, KLERSY, CATHERINE, DE SOUSA, JOÃO, OKREGLICKI, ANDRZEJ, ARENAL, ANGEL, WIJFFELS, MAURITS, LEMKE, BERND
Format: Article
Language:English
Subjects:
Defibrillators, Implantable
Electric Countershock - methods
Humans
implantable cardioverter/defibrillator
interval prolongation
prospective randomized trial
Research Design
Tachycardia, Ventricular - diagnosis
Tachycardia, Ventricular - prevention & control
therapy detection
Treatment Outcome
ventricular tachyarrhythmia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: The purpose of this investigation is to evaluate whether a prolonged detection interval for life threatening ventricular tachyarrhythmia (VT) is able to reduce therapies (Rx) delivered by an implantable cardioverter/defibrillator (ICD). Until now, only the PREPARE trial demonstrated a reduction of ICD Rx in a cohort of primary prevention patients. Methods and Results: The ADVANCE III study is a prospective, randomized, parallel trial with 2 arms evaluating different intervals to detect (NID), i.e., 18/24 (as currently used) versus 30/40. The primary endpoint is to demonstrate a 20% reduction of ICD Rx (antitachycardia pacing or shocks) delivered to terminate spontaneous VT with a cycle length ≤320 ms in patients with Class I‐IIA indication for ICD therapy, regardless of cardiac resynchronization capabilities. The worldwide investigation started in spring 2008 and is expected to be finished in 2011. Conclusions: The ADVANCE III trial is the first randomized investigation evaluating the reduction of ICD Rx for fast VT due to a prolongation of NID in a general ICD patient cohort.
ISSN:1045-3873
1540-8167
DOI:10.1111/j.1540-8167.2008.01415.x